

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

APR. 16. 2004 3:01PM

PIPER RUDNICK LLP

NO. 035 P. 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614 Customer No.: 035811
Examiner :
Serial No. : 10/735,512
Filed : December 12, 2003
Inventor : Salman Al-Mahmood Docket No.: 1414-03
Title : ANTISENSE OLIGONUCLEOTIDES
: CAPABLE OF INHIBITING THE Confirmation No.: 6845
: FORMATION OF CAPILLARY TUBES
: BY ENDOTHELIAL CELLS

Dated: April 16, 2004

Attn: Application Processing Division
Customer Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Facsimile

For

Request for Corrected Filing Receipt
Filing Receipt with Corrections Noted
Supplemental Application Data Sheet

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Piper Rudnick LLP
Customer No. 035811

By: PRDate: 16 APR 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	: 1614	Customer No.:	035811
Examiner	:		
Serial No.	: 10/735,512		
Filed	: December 12, 2003		
Inventor	: Salman Al-Mahmood	Docket No.:	1414-03
Title	: ANTISENSE OLIGONUCLEOTIDES	Confirmation No.:	6845
	: CAPABLE OF INHIBITING THE		
	: FORMATION OF CAPILLARY TUBES		
	: BY ENDOTHELIAL CELLS		
		Dated:	April 16, 2004

REQUEST FOR CORRECTED FILING RECEIPT


Attn: Application Processing Division
Customer Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are in receipt of the official filing receipt. A Supplemental Application Data Sheet is enclosed. Under Applicant(s) please change Applicant's name from "Salmon Al-Mahmood" to -- Salman Al-Mahmood --. Under Domestic Priority data as claimed by applicant, please change "06/14/2001" to -- 06/14/2002 --. Under Title, please change "Antisenseoligonucleotides" to -- Antisense oligonucleotides --. A copy of the filing receipt with the corrections noted is enclosed.

We look forward to receiving a corrected filing receipt in due course.

Respectfully submitted,


T. Daniel Christenbury
Reg. No. 31,750

TDC:ks
(215) 656-3381

APR. 16. 2004 3:02PM

PIPER RUDNICK LLP

NO. 035 P. 31 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1452
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/735,512	12/12/2003	1614	770	1414-03	5	18	2

035811

IP DEPARTMENT OF PIPER RUDNICK LLP
3400 TWO LOGAN SQUARE
18TH AND ARCH STREETS
PHILADELPHIA, PA 19103

CONFIRMATION NO. 6845

FILING RECEIPT

OC000000012149403

RECEIVED

MAR 29 2004

Date Mailed: 03/22/2004

IP DEPT.

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

^a
Salmon Al-Mahmood, Paris, FRANCE;

Assignment For Published Patent Application

Gene Signal, a corporation of France, Evry, FRANCE;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/FR02/02067 06/14/200²

Foreign Applications

FRANCE 01/07805 07/14/2001

If Required, Foreign Filing License Granted: 03/19/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells

extended
edit

cells

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).